__NUXT_JSONP__("/drugs/Anti-NY-ESO1LAGE-1A_TCRscFv_Anti-CD3_IMCnyeso", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A bispecific molecule composed of a soluble, affinity-enhanced T-cell receptor (TCR) specific for human leukocyte antigen A2 (HLA-A2)-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), fused to a single-chain variable fragment (scFv) specific for the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon infusion, anti-NY-ESO1\u002FLAGE-1A TCR\u002FscFv anti-CD3 IMCnyeso specifically targets and binds with its TCR moiety to NY-ESO-1 and\u002For LAGE-1A expressed on tumor cells and with its scFv moiety to CD3 expressed on T-cells. This crosslinks tumor cells and T-cells, re-directs and activates T-cells, and results in a cytotoxic T-lymphocyte (CTL)-mediated destruction of NY-ESO-1 and\u002For LAGE-1A-positive tumor cells. NY-ESO-1 and LAGE-1A, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types; they share a specific HLA-A*0201 epitope, 157-165, which is expressed on certain tumor cell types while its expression is not found on normal, healthy cells.",fdaUniiCode:"C416JC9CX0",identifier:"C153130",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129820"],synonyms:[c,"Bispecific NY-ESO-1- and LAGE-1A-specific TCR\u002FAnti-CD3","HLA- A*0201-Restricted NY-ESO-1- and LAGE-1A-specific Soluble TCR\u002FAnti-CD3 Bispecific Molecule","IMCNYESO","IMCnyeso"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAnti-NY-ESO1LAGE-1A_TCRscFv_Anti-CD3_IMCnyeso",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Anti-NY-ESO1LAGE-1A_TCRscFv_Anti-CD3_IMCnyeso","Anti-NY-ESO1\u002FLAGE-1A TCR\u002FscFv Anti-CD3 IMCnyeso","2021-10-30T13:33:59.823Z")));